Compare Quest Diagnostics Inc (DGX) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs KeyCorp — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.23B), while KeyCorp trades at $22.7 (market cap $24.31B). The key difference: Quest Diagnostics Inc and KeyCorp are close in size by market cap, and KeyCorp pays the higher dividend (3.62%). Which is the better fit depends on your goals.
| DGX | KEY | |
|---|---|---|
Market Cap | $26.23B | $24.31B |
Sector | Health | Financials |
52-Week High | $238.50 | $23.99 |
52-Week Low | $173.49 | $16.78 |
Enterprise Value | $31.99B | — |
Dividend Yield | 1.45% | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $238.35, down slightly by 0.06% today, but maintains a bullish technical trend with strong earnings momentum, having beaten EPS estimates in the last three quarters. Revenue grew to $11.04 billion in 2025, with net income reaching $992 million, and the company raised its 2026 outlook amid surging testing demand. Analyst consensus is a Buy with a $249.50 price target, though valuation multiples like a P/E of 25.3 suggest premium pricing.
The outlook for DGX is positive due to robust demand for diagnostic services, AI integration, and partnerships driving growth, but risks include margin pressure from lower-margin deals and high debt levels. Investors may find opportunity in sustained earnings beats and dividend payouts, yet should monitor competitive and cost pressures that could affect profitability.
KeyCorp (KEY) trades at $22.73, up 0.31% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.41. Recent Q2 2026 earnings beat estimates with EPS of $0.44, driven by net interest income growth and fee expansion. The acquisition of Clearwater UK bolsters its investment banking presence, while a 3.6% dividend yield adds income appeal.
Outlook is positive with earnings momentum and strategic acquisitions supporting growth, but risks include interest rate sensitivity and competitive pressures. Wall Street sentiment is bullish with 61% buy ratings, though net cash flow volatility and modest ROE of 2.72% warrant caution for value-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
